Drugs / 64Cu-PSMA I&T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05653856 | Dec 2022 → May 2023 | metastatic prostate carcinoma | Curium US LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-PSMA I&T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05653856 ↗ |
| Modality | Diagnostic / imaging agent | “Radiolabeled Receptor-Targeted Diagnostic Product” NCT05653856 ↗ |
| Route | Intravenous | “7-9 mCi intravenous dose” NCT05653856 ↗ |